These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25799919)

  • 21. Neurosteroid vitamin D system as a nontraditional drug target in neuropsychopharmacology.
    Stewart A; Wong K; Cachat J; Elegante M; Gilder T; Mohnot S; Wu N; Minasyan A; Tuohimaa P; Kalueff AV
    Behav Pharmacol; 2010 Sep; 21(5-6):420-6. PubMed ID: 20571365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP).
    Fusar-Poli P; Bauer M; Borgwardt S; Bechdolf A; Correll CU; Do KQ; Domschke K; Galderisi S; Kessing LV; Koutsouleris N; Krebs MO; Lennox B; McGuire P; Meyer-Lindenberg A; Millan MJ; Nieman D; Pfennig A; Sand M; Whenert A; van Amelsvoort T; Arango C
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1301-1311. PubMed ID: 31606303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetics of psychoactive drugs.
    Boyadjieva N; Varadinova M
    J Pharm Pharmacol; 2012 Oct; 64(10):1349-58. PubMed ID: 22943166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.
    Bosia M; Pigoni A; Cavallaro R
    Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetic considerations in the treatment of psychiatric disorders.
    Lohoff FW; Ferraro TN
    Expert Opin Pharmacother; 2010 Feb; 11(3):423-39. PubMed ID: 20102306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology of epigenetics in brain disorders.
    Narayan P; Dragunow M
    Br J Pharmacol; 2010 Jan; 159(2):285-303. PubMed ID: 20015091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations.
    Lang UE; Jockers-Scherübl MC; Hellweg R
    J Neural Transm (Vienna); 2004 Mar; 111(3):387-411. PubMed ID: 14991461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The developing utility of zebrafish models of neurological and neuropsychiatric disorders: A critical review.
    Fontana BD; Mezzomo NJ; Kalueff AV; Rosemberg DB
    Exp Neurol; 2018 Jan; 299(Pt A):157-171. PubMed ID: 28987462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain Derived Neurotrophic Factor: epigenetic regulation in psychiatric disorders.
    Mitchelmore C; Gede L
    Brain Res; 2014 Oct; 1586():162-72. PubMed ID: 25223903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of the cytoskeleton by Disrupted-in-schizophrenia 1 (DISC1).
    Wang Q; Brandon NJ
    Mol Cell Neurosci; 2011 Dec; 48(4):359-64. PubMed ID: 21757008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The epigenetic bottleneck of neurodegenerative and psychiatric diseases.
    Sananbenesi F; Fischer A
    Biol Chem; 2009 Nov; 390(11):1145-53. PubMed ID: 19747081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leading compounds for the validation of animal models of psychopathology.
    Micale V; Kucerova J; Sulcova A
    Cell Tissue Res; 2013 Oct; 354(1):309-30. PubMed ID: 23942897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaco-EEG Studies in Animals: An Overview of Contemporary Translational Applications.
    Drinkenburg WH; Ruigt GS; Ahnaou A
    Neuropsychobiology; 2015; 72(3-4):151-64. PubMed ID: 26901596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neural networks in psychiatry.
    Hulshoff Pol H; Bullmore E
    Eur Neuropsychopharmacol; 2013 Jan; 23(1):1-6. PubMed ID: 23394870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulated translational control in brain disorders: from genes to behavior.
    Wiebe S; Nagpal A; Sonenberg N
    Curr Opin Genet Dev; 2020 Dec; 65():34-41. PubMed ID: 32535350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.
    Mestre TA; Zurowski M; Fox SH
    Expert Opin Investig Drugs; 2013 Apr; 22(4):411-21. PubMed ID: 23409724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of genomic studies on neuropsychopharmacology. Proceedings of the 2nd European College of Neuropsychopharmacology (ECNP) Workshop. March 15-18, 2001, Nice, France.
    Eur Neuropsychopharmacol; 2001 Dec; 11(6):385-499. PubMed ID: 12094772
    [No Abstract]   [Full Text] [Related]  

  • 39. Testosterone in the brain: neuroimaging findings and the potential role for neuropsychopharmacology.
    Höfer P; Lanzenberger R; Kasper S
    Eur Neuropsychopharmacol; 2013 Feb; 23(2):79-88. PubMed ID: 22578782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Saba"--application of knowledge and state-of-the-art technologies in the field of psychiatry for development of new diagnostics prevention and therapeutic tools for schizophrenia.
    Kielan K; Kucharska-Pietura K; Warchala A; Konopka M; Pieniazek P; Hartel M
    Wiad Lek; 2004; 57 Suppl 1():152-7. PubMed ID: 15884228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.